10 results
PRER14A
QTNTQ
Quotient Ltd
26 Jul 22
Preliminary revised proxy
4:02pm
her career at Sanofi Pharmaceuticals in the cardiovascular R&D department before joining Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) where
PRE 14A
QTNTQ
Quotient Ltd
15 Jul 22
Preliminary proxy
4:30pm
of Health (LIH). Dr. Catherine Larue began her career at Sanofi Pharmaceuticals in the cardiovascular R&D department before joining Sanofi Diagnostics
8-K
EX-99.1
QTNTQ
Quotient Ltd
24 Jun 22
Results of Operations and Financial Condition
8:02am
an international partnership with Centre Pasteur du Cameroon (CPC) for the IIR program. This partnership will provide Quotient’s R&D team with rare HIV samples
8-K
EX-99.1
QTNTQ
Quotient Ltd
16 Nov 21
Quotient Limited Provides Second Quarter Fiscal 2022 Results
12:00am
million or 15.8% compared to the second quarter of the prior fiscal year. This increase is primarily driven by higher R&D spend related
8-K/A
EX-99.1
w6l1ngf7luw44mqju
1 Jun 21
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
12:27pm
8-K
EX-99.1
cv9mdtonyj
1 Jun 21
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
6:30am
8-K
su70r
23 Jul 20
Termination of a Material Definitive Agreement
8:02am
- Prev
- 1
- Next